A phase 2 clinical trial demonstrated a case of adoptive transfer of autologous mutant-protein-specific TILs in association with pembrolizumab and interleukin-2 that led to the complete and durable regression of metastatic disease in an HR-positive BC patient who failed to respond to multiple previous lines of therapy (77). The gene discussed is IL2; the disease is breast cancer.